59. Cole MD, Nikiforov MA (2006) Transcriptional activation by the Myc oncoprotein. Curr Top Microbiol Immunol 302: 33–50. 60. von Eyss B, Eilers M (2011) Addicted to Myc–but why? Genes Dev 25: 895–897. 61. Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22: 6151–6159. 62. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, et al. (2010) In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074- G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther 335: 715–727. 63. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM (1997) Phenotypes of c-Myc- deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8: 1039–1048. The Action Mechanism of Omomyc 64. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90: 8392–8396. 65. Ciarapica R, Annibali D, Raimondi L, Savino M, Nasi S, et al. (2009) Targeting Id protein interactions by an engineered HLH domain induces human neuroblastoma cell differentiation. Oncogene 28: 1881–1891. 66. Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, et al. (2004) Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med 200: 1257–1266. PLoS ONE | www.plosone.org 16 July 2011 | Volume 6 | Issue 7 | e22284